These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37256266)

  • 1. Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice.
    Kaufmann B; de Los Reyes Jiménez M; Booshehri LM; Onyuru J; Leszczynska A; Uri A; Michel S; Klar R; Jaschinski F; Feldstein AE; Broderick L; Hoffman HM
    J Immunol; 2023 Jul; 211(2):287-294. PubMed ID: 37256266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors.
    Bertoni A; Carta S; Baldovini C; Penco F; Balza E; Borghini S; Di Duca M; Ognio E; Signori A; Nozza P; Schena F; Castellani P; Pastorino C; Perrone C; Obici L; Martini A; Ceccherini I; Gattorno M; Rubartelli A; Chiesa S
    J Allergy Clin Immunol; 2020 Jan; 145(1):368-378.e13. PubMed ID: 31194989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CANE, a Component of the NLRP3 Inflammasome, Promotes Inflammasome Activation.
    Kaneko N; Kurata M; Yamamoto T; Sakamoto A; Takada Y; Kosako H; Takeda H; Sawasaki T; Masumoto J
    J Immunol; 2024 Jul; 213(1):86-95. PubMed ID: 38787200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice.
    Frising UC; Ribo S; Doglio MG; Malissen B; van Loo G; Wullaert A
    EMBO Rep; 2022 Jul; 23(7):e54339. PubMed ID: 35574994
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Nakanishi H; Kawashima Y; Kurima K; Chae JJ; Ross AM; Pinto-Patarroyo G; Patel SK; Muskett JA; Ratay JS; Chattaraj P; Park YH; Grevich S; Brewer CC; Hoa M; Kim HJ; Butman JA; Broderick L; Hoffman HM; Aksentijevich I; Kastner DL; Goldbach-Mansky R; Griffith AJ
    Proc Natl Acad Sci U S A; 2017 Sep; 114(37):E7766-E7775. PubMed ID: 28847925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.
    Brydges SD; Broderick L; McGeough MD; Pena CA; Mueller JL; Hoffman HM
    J Clin Invest; 2013 Nov; 123(11):4695-705. PubMed ID: 24084736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP.
    Lee GS; Subramanian N; Kim AI; Aksentijevich I; Goldbach-Mansky R; Sacks DB; Germain RN; Kastner DL; Chae JJ
    Nature; 2012 Dec; 492(7427):123-7. PubMed ID: 23143333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
    PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndrome.
    Karasawa T; Komada T; Yamada N; Aizawa E; Mizushina Y; Watanabe S; Baatarjav C; Matsumura T; Takahashi M
    Elife; 2022 May; 11():. PubMed ID: 35616535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome.
    Hu J; Zhu Y; Zhang JZ; Zhang RG; Li HM
    Chin Med J (Engl); 2017 Mar; 130(5):586-593. PubMed ID: 28229991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production.
    Molina-López C; Hurtado-Navarro L; García CJ; Angosto-Bazarra D; Vallejo F; Tapia-Abellán A; Marques-Soares JR; Vargas C; Bujan-Rivas S; Tomás-Barberán FA; Arostegui JI; Pelegrin P
    Nat Commun; 2024 Feb; 15(1):1096. PubMed ID: 38321014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoliquiritigenin inhibits NLRP3 inflammasome activation with CAPS mutations by suppressing caspase-1 activation and mutated NLRP3 aggregation.
    Usui-Kawanishi F; Kani K; Karasawa T; Honda H; Takayama N; Takahashi M; Takatsu K; Nagai Y
    Genes Cells; 2024 May; 29(5):423-431. PubMed ID: 38366709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Nlrp3 knock-in mouse model with hyperactive inflammasome in development of lethal inflammation.
    Zhou Y; Yang X; Zhu L
    Clin Exp Immunol; 2024 Feb; 215(2):202-214. PubMed ID: 37594231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux.
    He Y; Zeng MY; Yang D; Motro B; Núñez G
    Nature; 2016 Feb; 530(7590):354-7. PubMed ID: 26814970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome.
    Stackowicz J; Gaudenzio N; Serhan N; Conde E; Godon O; Marichal T; Starkl P; Balbino B; Roers A; Bruhns P; Jönsson F; Moguelet P; Georgin-Lavialle S; Broderick L; Hoffman HM; Galli SJ; Reber LL
    J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34477811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linkage of bacterial colonization of skin and the urticaria-like rash of NLRP3-mediated autoinflammatory syndromes through mast cell-derived TNF-α.
    Nakamura Y; Kambe N
    J Dermatol Sci; 2013 Aug; 71(2):83-8. PubMed ID: 23684246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies.
    Moltrasio C; Romagnuolo M; Marzano AV
    Front Immunol; 2022; 13():1007705. PubMed ID: 36275641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.
    Kuemmerle-Deschner JB; Verma D; Endres T; Broderick L; de Jesus AA; Hofer F; Blank N; Krause K; Rietschel C; Horneff G; Aksentijevich I; Lohse P; Goldbach-Mansky R; Hoffman HM; Benseler SM
    Arthritis Rheumatol; 2017 Nov; 69(11):2233-2240. PubMed ID: 28692792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction.
    Ito S; Hara Y; Kubota T
    Arthritis Res Ther; 2014 Feb; 16(1):R52. PubMed ID: 24517500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
    Marchetti C; Swartzwelter B; Gamboni F; Neff CP; Richter K; Azam T; Carta S; Tengesdal I; Nemkov T; D'Alessandro A; Henry C; Jones GS; Goodrich SA; St Laurent JP; Jones TM; Scribner CL; Barrow RB; Altman RD; Skouras DB; Gattorno M; Grau V; Janciauskiene S; Rubartelli A; Joosten LAB; Dinarello CA
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1530-E1539. PubMed ID: 29378952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.